Aerosol delivery of orally inhaled agents

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 25, Issue SUPPL.1, 2012, Pages

  Corcoran, Timothy E ^a   Devadason, Sunalene G ^b   Kuehl, Philip J ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

aerosol deposition; PET; scintigraphy; SPECT

Indexed keywords

RADIOPHARMACEUTICAL AGENT; DRUG;

ACCURACY; AEROSOL; DEPOSITION SCINTIGRAPHY; DRUG EFFECT; DRUG METABOLISM; HUMAN; INHALATIONAL DRUG ADMINISTRATION; ISOTOPE LABELING; MULTICENTER STUDY (TOPIC); PHARMACEUTICAL EQUIVALENCE; POSITRON EMISSION TOMOGRAPHY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ARTICLE; DRUG DELIVERY SYSTEM; LUNG; METABOLISM; METHODOLOGY; SCINTISCANNING; STANDARD; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; PHARMACEUTICAL PREPARATIONS; RADIONUCLIDE IMAGING; TISSUE DISTRIBUTION;

EID: 84870844342     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2012.1Su2     Document Type: Review

References (20)

1. Snell NJ, and Ganderton D: Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. Respir Med. 1999;93:123-133. (Pubitemid 29062720)
2. Scheuch G, Bennett W, Borgstrom L, Clark A, Dalby R, Dolovich M, Fleming J, Gehr P, Gonda I, O'Callaghan C, Taylor G, and Newman S: Deposition, imaging, and clearance: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23 Suppl 2:S39-S57.
3. Heyder J, Gebhardt J, Rudolf G, Schiller CF, and Stahlhofen W: Deposition of particles in the human respiratory tract in the size range of 0.005-15 micron. J Aerosol Sci. 1986;17:811-825. (Pubitemid 17492310)
4. Svartengren K, Lindestad PA, Svartengren M, Bylin G, Philipson K, and Camner P: Deposition of inhaled particles in the mouth and throat of asthmatic subjects. Eur Respir J. 1994;7:1467-1473. (Pubitemid 24268334)
5. Ilowite JS, Gorvoy JD, and Smaldone GC: Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis. 1987;136:1445-1449. (Pubitemid 18030280)
6. Gillett MK, Briggs BA, and Snashall PD: The influence of aerosol retention and pattern of deposition on bronchial responsiveness to atropine and methacholine in humans. Am Rev Respir Dis. 1989;140:1727-1733. (Pubitemid 20041060)
7. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, Lemaire F, Long W, Zaccardelli DS, and Pattishall EN: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med. 1996;334:1417-1421. (Pubitemid 26157436)
8. Matthay MA: The acute respiratory distress syndrome. N Engl J Med. 1996;334:1469-1470. (Pubitemid 26157444)
9. Laube BL, Edwards AM, Dalby RN, Creticos PS, and Norman PS: The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma. J Allergy Clin Immunol. 1998;101(4 Pt 1):475-483. (Pubitemid 28208251)
10. Usmani OS, Biddiscombe MF, and Barnes PJ: Regional lung deposition and bronchodilator response as a function of b2- agonist particle size. Am J Respir Crit Care Med. 2005;172: 1497-1504. (Pubitemid 43076536)
11. Iacono AT, Smaldone GC, Keenan RJ, Diot P, Dauber JH, Zeevi A, Burckart GJ, and Griffith BP: Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am J Respir Crit Care Med. 1997;155:1690-1698. (Pubitemid 27216679)
12. Corcoran TE, Smaldone GC, Dauber JH, Smith DA, McCurry KR, Burckart GJ, Zeevi A, Griffith BP, and Iacono AT: Preservation of post-transplant lung function with aerosol cyclosporin. Eur Respir J. 2004;23:378-383. (Pubitemid 38344372)
13. Cass LM, Brown J, Pickford M, Fayinka S, Newman SP, Johansson CJ, and Bye A: Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet. 1999;36 Suppl 1:21-31. (Pubitemid 29322454)
14. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, and Weers JG: Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers. Chest. 2003;124:360-366. (Pubitemid 36851374)
15. Diot P,RivoireB, Le PapeA, Lemarie E,DireD, FuretY, Breteau M, and SmaldoneGC:Deposition of amphotericin b aerosols in pulmonary aspergilloma. Eur Respir J. 1995;8:1263-1268.
16. Behr J, Zimmermann G, Baumgartner R, Leuchte H, Neurohr C, Brand P, Herpich C, Sommerer K, Seitz J, Menges G, Tillmanns S, and Keller M: Lung deposition of a liposomal cyclosporine a inhalation solution in patients after lung transplantation. J Aerosol Med Pulm Drug Deliv. 2009;22:121-130.
17. Rogers DF, and Ganderton D: Determining equivalence of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at Royal Brompton National Heart & Lung Institute, London 24 June 1994. Respir Med. 1995;89:253-261.
18. O'Connor D, Adams WP, Chen ML, Daley-Yates P, Davis J, DerendorfH,DucharmeMP, Fuglsang A, HerrleM, Hochhaus G, Holmes SM, Lee SL, Li BV, Lyapustina S, Newman S, Oliver M, Patterson B, Peart J, Poochikian G, Roy P, Shah T, Singh GJ, and Sharp SS: Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J AerosolMed PulmDrug Deliv. 2011;24:119-135.
19. Adams WP, Ahrens RC, Chen ML, Christopher D, Chowdhury BA, Conner DP, Dalby R, Fitzgerald K, Hendeles L, Hickey AJ, Hochhaus G, Laube BL, Lucas P, Lee SL, Lyapustina S, Li B, O'Connor D, Parikh N, Parkins DA, Peri P, Pitcairn GR, Riebe M, Roy P, Shah T, Singh GJ, Sharp SS, Suman JD, Weda M, Woodcock J, and Yu L: Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): workshop summary report. J Aerosol Med Pulm Drug Deliv. 2010;23:1-29.
20. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. CPMP/ EWP/4151/00 Rev. 1 ED: European Medicines Agency; 2009.